Age-Related Macular Degeneration Ryan Initiative Study (ARIS)
- Sponsor: National Eye Institute
- Principal Investigator: Barbara Blodi, MD
- Study coordinator: Kris Dietzman
Study objective:
To understand the progression of age-related macular degeneration from early to late-stage disease
Study design:
Subjects will have annual study visits for up to 5 years. During study visits subjects will undergo clinical assessments, multi-modal imaging and receive the standard of care as determined by their ophthalmologist.
Inclusion criteria:
- Men and women aged 55 and older;
- Clinical and Reading Center verification:
- Cohort 1 – Early AMD, N=200 (Medium drusen >63mu and less than or equal to 125mu) OU
- Cohort 2 – RPD, N=200, (2A)At least one eye with RPD with no large drusen (>125mu) in either eye; (2B)At least one eye with RPD with >=1 large drusen (>125mu) in either eye (n=100)
- Cohort 3 – Controls, N=100, No drusen >63mu, no RPD or pigmentary changes OU
- Best Corrected Visual Acuity of 20/25 or better
Exclusion criteria:
- Any evidence of late AMD (i.e. CNV or GA) in either eye
- Previous retinal or other ocular surgical procedures, the effects of which may now or in the future complicate assessment of the progression of AMD in the Investigator’s opinion
- Participants with a current IOP > 26, a history of the diagnosis of increased intraocular pressure, glaucoma, past or present use of medications to control intraocular pressure, or disc/nerve fiber layer defects suggestive of glaucoma can be eligible if the absence of a glaucomatous visual field defect can be documented by a normal Goldmann, Humphrey or Octopus perimetry test within six months prior to qualification.
Contact Kris Dietzman with questions: 608-263-9035.
For more information about this study: